An improved process for repaglinide via an efficient and one pot process of (1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butan-1-amine -: A useful intermediate

被引:0
作者
Kolla, Naveenkumar
Elati, Chandrashekar R.
Vankawala, Pravinchandra J.
Gangula, Srinivas
Sajja, Eswaraiah
Anjaneyulu, Yerremilli
Bhattacharya, Apurba
Sundaram, Venkataraman
Mathad, Vijayavitthal T. [1 ]
机构
[1] Dr Reddys Labs Ltd, Dept Res & Dev, IPD, Unit 3, Medak 502325, Andhra Pradesh, India
[2] JNT Univ, Ctr Atmospher Sci, Hyderabad 500072, Andhra Pradesh, India
关键词
1,3-dicyclohexyl urea impurity; Grignard reaction; racemization; repaglinide; resolution; SNAR reaction; telescopic process;
D O I
10.2533/chimia.2006.593
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The development of a large-scale synthesis for (1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butan-1-amine (S-(+)-1), a key intermediate of repaglinide (2), is described. The process conditions for S-(+)-1 involving nucleophilic substitution, Grignard reaction, reduction and resolution were optimized and telescoped. The racemization of the undesired enantiomer R-(-)-1 offers a distinctive advantage in terms of cost and overall yield over the existing process. This communication also describes the control of a DCU byproduct obtained during the condensation of S-(+)-1 with phenyl acetic acid derivative 3 in the synthesis of 2.
引用
收藏
页码:593 / 597
页数:5
相关论文
共 7 条
[1]  
Araceli P., 2005, DIABETES CARE, V28, P1789
[2]   Repaglinide and related hypoglycemic benzoic acid derivatives [J].
Grell, W ;
Hurnaus, R ;
Griss, G ;
Sauter, R ;
Rupprecht, E ;
Mark, M ;
Luger, P ;
Nar, H ;
Wittneben, H ;
Müller, P .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (26) :5219-5246
[3]  
Grell W., 1994, US, Patent No. 5312924
[4]  
MANNE SR, 2004, Patent No. 249188
[5]  
MOHAMMAD S, 2002, ORG PROCESS RES DEV, V6, P184
[6]  
RAY PC, 2003, Patent No. 027072
[7]   EFFECTS OF A NEW ORAL HYPOGLYCEMIC AGENT, REPAGLINIDE, ON METABOLIC CONTROL IN SULFONYLUREA-TREATED PATIENTS WITH NIDDM [J].
WOLFFENBUTTEL, BHR ;
NIJST, L ;
SELS, JPJE ;
MENHEERE, PPCA ;
MULLER, PG ;
KRUSEMAN, ACN .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 45 (02) :113-116